Navigation Links
Potential new drug candidate found for Alzheimer's disease
Date:5/31/2011

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid (Aβ) in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

A paper detailing the findings has been published as an early online version and is scheduled for publication in the September 6 issue of the Journal of Alzheimer's Disease.

According to lead investigator Vivian Y. H. Hook, PhD, professor of the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, this is major news for scientists studying Alzheimer's disease.

"The finding is especially exciting because E64d has previously been shown safe for use in humans, so we believe the compound has strong potential as a new therapy for Alzheimer's disease," said Hook.

Increased Aβ levels in the brain are associated with the development of memory loss and amyloid plaque, the hallmark of Alzheimer's disease. Aβ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) by an enzymatic "scissor" called β-secretase, and aggregate to form plaques in the brain regions responsible for memory.

E64d reduces Aβ by inhibiting the β-secretase "scissors" from "cutting" the APP chain into smaller toxic Aβ peptides. But in this study, the researchers found that the compound actually increases the activity of a protease called BACE1 which, to date, has been regarded as the primary β-secretase. Instead, E64d appears to lower brain Aβ by inhibiting the β-secretase activity of another protease, Cathepsin B.

"The study indicates Cathepsin B as a new target for therapeutic inhibition of Aβ production and subsequent improved memory function," said Hook. "This is an important finding because we show that β-secretase inhibition can occur with Cathepsin B inhibition and without BACE1 inhibition."

The researchers studied both old and young transgenic Alzheimer's disease mice, and found that memory loss improved in both. In young mice, feeding E64d prevented development of memory loss; in old mice with memory loss, it improved memory.

The study builds upon work published in March 2008 that first demonstrated that inhibitors of Cathepsin B resulted in improved memory and reduction of Aβ and amyloid plaque; but in that study, the drug was administered directly into the brains of AD mice. In the new study, oral administration of the drug was efficacious and could lead the way to clinical trials in humans.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. The Potential to Modify the Course of Parkinsons Disease
2. Potentially Toxic Flame Retardants Found in Baby Products
3. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
4. Study shows pharmacies software systems miss potentially dangerous interactions
5. Experts explore digital technologies potential to improve health care
6. Most nurses dont use recommended intramuscular injection site despite potential risks
7. A potential novel drug-target for colorectal cancer treatment comes from the brain
8. Potential diagnostic test for Alzheimers would use cerebrospinal fluid
9. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
10. Accountable care organizations have potential to curb costs and improve health care
11. Potential new strategy to reduce catheter blockage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology: